Page 7 - Ivir News Today

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) hit a new 52-week low on Thursday after Morgan Stanley lowered their price target on the stock from $27.00 to $15.00. Morgan Stanley currently has an equal weight rating on the stock. Vir Biotechnology traded as low as $13.16 and last traded at $13.41, with a volume […]

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price lowered by Barclays from $59.00 to $41.00 in a research note issued to investors on Friday, FlyOnTheWall reports. Barclays‘s price objective suggests a potential upside of 222.83% from the stock’s current price. Other analysts have also recently issued reports about the company. Needham & […]

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price decreased by equities researchers at Barclays from $59.00 to $41.00 in a research report issued to clients and investors on Friday, FlyOnTheWall reports. Barclays‘s price target points to a potential upside of 222.83% from the company’s current price. A number of other equities research […]

Vir Biotechnology Inc. said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals, sending the stock down 40%...

VIR | Complete Vir Biotechnology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

It was one of the hot stocks of the early pandemic era, its shares climbing more than 500% between the start of 2020 and the biotechnology sector’s peak in...

By Colin Kellaher Vir Biotechnology on Thursday said a Phase 2 study of its VIR-2482 candidate for the prevention of symptomatic influenza A illness missed...

By Colin Kellaher Vir Biotechnology shares slid more than 40% and hit a new multi-year low Thursday after the immunology company reported the failure of a...

It was one of the hot stocks of the early pandemic era, its shares climbing more than 500% between the start of 2020 and the biotechnology sector’s peak in...

Around 200 representatives will gather at a health conference on July 20 to discuss innovative approaches to pharma-healthcare development.